US2023287353A1PendingUtilityA1

Differentiation of human embryonic stem cells

83
Assignee: JANSSEN BIOTECH INCPriority: Nov 27, 2007Filed: Oct 18, 2022Published: Sep 14, 2023
Est. expiryNov 27, 2027(~1.3 yrs left)· nominal 20-yr term from priority
Inventors:Alireza Rezania
C12N 5/0676C12N 5/0678C12N 2501/105C12N 2501/117C12N 2501/12C12N 2501/155C12N 2501/16C12N 2501/335C12N 2501/385C12N 2501/41C12N 2501/415C12N 2501/42C12N 2501/70C12N 2501/998C12N 2501/999C12N 2506/02C12N 2533/90A61P 1/18C12N 2501/15C12N 2501/40C12N 2501/727
83
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods to promote the differentiation of pluripotent stem cells and the products related to or resulting from such methods. In particular, the present invention provides an improved method for the formation of pancreatic hormone expressing cells and pancreatic hormone secreting cells. In addition, the present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer and the products related to or resulting from such methods. The present invention also provides methods to promote glucose-stimulated insulin secretion in insulin-producing cells derived from pluripotent stem cells.

Claims

exact text as granted — not AI-modified
1 . A composition, comprising human pancreatic endoderm cells, human pancreatic endocrine cells, and an effective amount of noggin and an ALK5 inhibitor, wherein the noggin and the ALK5 inhibitor differentiate the human pancreatic endoderm cells into human pancreatic endocrine cells. 
     
     
         2 . The composition of  claim 1 , wherein the ALK5 inhibitor is ALK5 inhibitor I. 
     
     
         3 . The composition of  claim 1 , wherein the ALK5 inhibitor is ALK5 inhibitor II. 
     
     
         4 . The composition of  claim 1 , wherein there are more human pancreatic endocrine cells than human pancreatic endoderm cells in the composition. 
     
     
         5 . The composition of  claim 1 , wherein the human pancreatic endoderm cells and/or the human pancreatic endocrine cells are derived from human embryonic stem cells. 
     
     
         6 . The composition of  claim 1 , wherein the human pancreatic endocrine cells express at least one of: NGN-3, NeuroD, Islet-1, PDX-1, PAX-4, and NKX2.2. 
     
     
         7 . The composition of  claim 1 , wherein the human pancreatic endocrine cells are β-cells. 
     
     
         8 . The composition of  claim 1 , wherein the human pancreatic endocrine cells express at least one of: H1xb9, PTF-1a, PDX-1, HNF-6, and HNF-1beta. 
     
     
         9 . The composition of  claim 1 , wherein the noggin is present in the composition at a concentration of about 500 ng/ml to about 500 μg/ml. 
     
     
         10 . The composition of  claim 1 , wherein the ALK inhibitor is present in the composition at a concentration of about 1 μM to about 10 μM.

Join the waitlist — get patent alerts

Track US2023287353A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.